AzTrials
AzTrials

Male InfertilityNCT04704141

Relationship of the Microenvironment and Male Fertility

An observational study of Male Infertility and Male Hypogonadism, run by University of Illinois Chicago at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Although much is known about the microenvironment of the gut and the vagina, very little has been published on the microenvironment of the seminal plasma. The seminal plasma is the support fluid for sperm, providing nutrients, facilitating sperm transit to the uterus, and promoting fertilization. Read more about this study

Who is it for?
Ages 18 years and older, men only
Conditions the study is for
Male Infertility, Male Hypogonadism
What is being tested?
Hormone replacement therapy
How many people
150 participants
Where
1 siteUnited States
Study dates
Jun 2023to Jun 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • Adult, Older adult

Study population: Males referred to University of Illinois Hospital Fertility Services

Who may be able to join

  • Men diagnosed with infertility who consent to participate in the study

Who cannot join

  • Prior hormone replacement therapy
  • Antibiotic use in past 6 months
  • Inability to consent for self, due to age or mental capacity
  • Infertility attributable to identifiable causes other than hypogonadism

Trial locations and contacts

1 site in 1 country.

Samuel Ohlander, MD contact

312-996-9330

sohlande@uic.edu

United States1 site
  • University of Illinois Hospital

    Chicago, Illinois, 60612

    Rodrigo Pagani, MD, 312-996-9330, rpagani@uic.edu

Other trials in United States

About this study

Official title: Relationship of the Gut and Genitourinary Tract Microenvironment and Male Fertility

Although much is known about the microenvironment of the gut and the vagina, very little has been published on the microenvironment of the seminal plasma. The seminal plasma is the support fluid for sperm, providing nutrients, facilitating sperm transit to the uterus, and promoting fertilization. It is a rich area of research for markers of fertility and treatment targets.

The investigators hypothesize that (1) there are significant populations of seminal microorganisms associated with seminal leukocyte counts well below the WHO's cutoff for pyospermia (1 million/mL) that were not previously detected by traditional culturing methods, and (2) there are pathologic populations of bacteria within the gut and semen microbiome which negatively impact overall fertility, by directly or indirectly impairing hormone status.

Read more

Participants will be recruited from the Male Fertility practice at the University of Illinois-Chicago (UIC). All participants will have infertility, diagnosed as an inability to conceive pregnancy after 12 months of unprotected intercourse. The normal evaluation of these participants is to obtain at least one semen analysis and bloodwork investigating their endocrine profile: total testosterone, estradiol, sex hormone binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and albumin. Semen volume is typically >1 mL, and <0.2 mL is typically used for the semen analysis. If over 1 million/mL round cells are identified, then a Papanicolaou stain would be performed to identify leukocytes. In this study, any semen demonstrated to have round cells would undergo Papanicolaou staining. A portion of the remaining semen, which would typically be discarded, will be sent for microbiome analysis.

Secondly, as part of routine care, fertility patients may be started on medications to increase endogenous testosterone (i.e.: clomiphene citrate, anastrozole, etc). Participants started on medications will also be asked to submit a rectal swab for gut microbiome analysis. Routine care is to monitor the hormonal and testicular response with periodic endocrine blood panels and semen analyses; rectal swabs will be requested at these follow-up intervals also. The control group for both hypotheses will be men with clinical infertility with normal semen analyses and hormone profiles.

Read the detailed description

Objectives:

  1. Characterize the microbiota of the genitourinary tract and testicular microenvironment in infertile men with leukocytes in the semen by using 16S rRNA sequencing to analyze the microbiome of de-identified semen samples, and compare the results of semen with normal parameters to the results of semen with leukocytes.
  2. Evaluate the influence of the gut microbiome on hormone replacement therapy in hypogonadal, infertile men who are being treated with hormone replacement therapy, by analyzing multiple de-identified blood samples and rectal swabs collected both before and over the course of standard hypogonadism treatment. The investigators will use 16S rRNA sequencing on the rectal swabs and hormone level analysis of the blood samples.

Identification and Enrollment: Participants who meet inclusion criteria will be identified in UIC Urology fertility clinics by attending physician co-investigators during routine chart review for standard patient care. The participant will then be approached regarding the study and discuss the following: informed consent and information within it, basic information about the human microenvironments and significance in layman's terms, and reinforce that participation in the study will have no impact on the participant's care. Consent to participate will be obtained if the participant elects to proceed. The participant will receive oral and written information about the study. The written information includes understandable information about the study with extensive information on the study and include a copy of the consent form.

These participants' medical records will be reviewed for basic data listed below, and if hypogonadal also periodically after routine blood draws (see Venipuncture below).

Participant information management: Participants' names, MRN, and DOB will be stored in a UIC REDCap database. Each participant will also be assigned a study identification number generated by a random number generator. This ID number will be used to label the respective participant's biospecimen.

Semen collection and storage: As part of standard infertility workup of men, a semen sample will be requested after the diagnosis of infertility is made. Semen will be prospectively collected by the UIC Andrology Laboratory (820 S Wood St, Room 132, Chicago, IL 60612).

Participants will be instructed on the following for sample collection (adapted from Hou et al.):

  1. Present for sample provision after 3-7 days of abstinence.
  2. Wash hands 2-3 times with soap and water prior to masturbation.
  3. Wash penis with a focus on glans and coronal sulcus with soap and water followed by 75% alcohol, 2-3 times.
  4. Avoid contact of specimen with inside side wall of sample container.
  5. 0.1 mL or less of freshly collected semen will be used for standard semen analysis.
  6. If semen is identified to have any number of round cells, then a leukocyte count will be determined by Papanicolaou staining.
  7. The remainder of semen will be transferred into microcentrifuge tubes, with up to 1 mL each tube, and stored in a -80C freezer within 2 hours of collection. The -80C freezer is in a locked room of the UIC Andrology Laboratory accessible to authorized personnel only.[7]

Venipuncture: Participants will have their blood drawn during standard initial evaluation of infertility. This will be performed either by UIC phlebotomy services (1801 W Taylor St Room 4B, Chicago, IL 60612) or any other phlebotomy site and laboratory based on participant preference. The endocrine profile will be determined by testing total testosterone, estradiol, sex hormone binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and albumin levels. A total of 4.9 mL venous blood is required for these tests and thus a total of 3 gold-topped vials would be drawn from a vein. Men determined to be hypogonadal (total testosterone <300 ng/dL or bioavailable testosterone <150 ng/dL) will be requested to provide a rectal swab as well (see below). As part of standard treatment of their condition, these participants will be started on medications to increase endogenous testosterone (ie: clomiphene citrate, anastrozole, human chorionic gonadotropin, etc). Additionally, as part of standard care, these participants will be requested to return for regular assessment of medication side effects and efficacy with laboratory monitoring of their endocrine profile. This is carried out in intervals of 3-4 months at the attending physician's discretion. The laboratory data of participants meeting inclusion criteria will be recorded in a de-identified REDCap database, identified by the study ID number.

Rectal swab collection: After review of laboratory results with the participant at the first follow-up appointment, if the participant is diagnosed with infertility secondary to hypogonadism with no other identifiable causes, he will be requested to provide rectal swabs for analysis of the gut microbiome. A rectal swab kit will be provided to the participant. After a bowel movement, the participant will be asked to use the swab to collect sample from the anus and return the sample in the provided sterile plastic bag. This will be stored in a secure, locked cabinet. A rectal swab will then be requested at the same time intervals as follow-up bloodwork, collected and stored in the same manner.

Microbiota profile characterization: Microbiota analysis will be performed by the Igenomix laboratory in Valencia, Spain (Ronda Narciso Monturiol, 11 B, Parque Tecnológico Paterna, 46980 - Paterna -, Valencia, Spain). Once the investigators have prospectively collected participant samples, semen and/or rectal swabs, the investigators will periodically send samples to Igenomix for processing, as logistically feasible. The investigators will send 1 sample of each type of specimen per participant as applicable (i.e. if a participant gave enough semen for 3 additional vials in our storage freezer, then 1 vial would be sent to Igenomix; if the participant is also hypogonadal then a rectal swab is sent if it is indicated and collected as described above). Each of these samples will be identified only by study ID number and will have no PHI. Only the study ID number associated with each vial and no other identifying information will be sent with the samples, ensuring that no PHI will ever be shared with Igenomix. Igenomix laboratory will perform microbiota profiling using 16S rRNA gene sequencing in each specimen. There will be no stored samples after the analysis, as all the material will be used for DNA extraction and subsequent sequencing. All acquired data will be uploaded into a separate UIC REDCap database, with each sample's dataset identified again only by study ID number.

Data analysis: Data analysis will be performed by Dr. Pagani and UIC co-investigators to analyze the data using de-identified data sets from participant chart review and those provided by the Igenomix laboratory.

Cursory analysis of microbiota data sets will determine the exact statistical analyses applicable to address our study objectives and hypotheses. The investigators will assess bacterial microbiome composition and abundance using statistics computational programs such as the R package (R Foundation for Statistical Computing, Vienna, Austria). The investigators will further characterize the bacterial communities by creating hierarchical clustering based on published methods such as described by Hou et al. (PMID: 23993888). Based on the resulting data, the investigators will choose the appropriate statistical procedure to test our 2 hypotheses.

Study completion: Participants will be followed for 12 months, allowing for 4 follow-up appointments and sample collections. At the conclusion of our study, the investigators will destroy any remaining biospecimen. All identifiable data will be purged from the REDCap database.

Being tested
Hormone replacement therapy
Keywords
Infertility, Microenvironment, Microbiome, Seminal Fluid
Medical subject headings
Infertility, Male, Eunuchism, Infertility

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Hormone replacement therapyDrug

    A hormone replacement regimen using any medication of a number of standard treatment options

Study groups in NCT04704141
Study groupRoleWhat they receive
Infertile men with leukocytes in semen and eugonadalStandard fertility evaluation and treatments
Infertile men without leukocytes in semen and eugonadalStandard fertility evaluation and treatments
Infertile men with hypogonadismStandard fertility evaluation and treatments, including hormone replacement therapy such as with clomiphene citrate
Receives: Drug: Hormone replacement therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Characterization of the Microbiota

    16S rRNA sequencing of bacterial DNA found in semen and rectal swab samples will be completed on all samples obtained from participants. This will characterize the microbiota profile of each sample.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jan 2021
  2. Study startJun 2023 (estimated)
  3. Primary completionJun 2025 (estimated)
  4. Study completionJun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04704141
Sponsor's protocol ID
2020-1586
Status last verified
Apr 2023
First submitted
7 Jan 2021
Last updated
20 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The investigators do not plan to make patient information available to other researchers.

Questions about this trial

What is this clinical trial studying?

An observational study of Male Infertility and Male Hypogonadism, run by University of Illinois Chicago at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Samuel Ohlander, MD (312-996-9330, sohlande@uic.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Characterization of the Microbiota (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in